Retraction to: Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis – usefulness of alendronate and risedronate (Expert Opinion on Pharmacotherapy, (2007), 8, 16, (2743-2756), 10.1517/14656566.8.16.2743);Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis - usefulness of alendronate and risedronate

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 16, 2007, Pages 2743-2756

  Iwamoto, Jun ^a   Takeda, Tsuyoshi ^a   Sato, Yoshihiro ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Mitate Hospital   (Japan)

Author keywords

Bisphosphonate; Fracture; Glucocorticoid; Male; Osteoporosis; Postmenopausal women

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DENOSUMAB; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

BONE NECROSIS; CALCIUM ABSORPTION; CALCIUM EXCRETION; CALCIUM HOMEOSTASIS; CALCIUM INTAKE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ESTROGEN DEFICIENCY; EYE INFLAMMATION; FEVER; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; KIDNEY TUBULE ABSORPTION; LEG CRAMP; MALE OSTEOPOROSIS; META ANALYSIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NEPHRITIS; OSSIFICATION; OSTEOMYELITIS; OSTEOPOROSIS; PAGET SKIN DISEASE; PATIENT COMPLIANCE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VERTEBRA FRACTURE; FEMALE; MALE; POSTMENOPAUSE OSTEOPOROSIS;

ALENDRONATE; ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 36048943867     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2019.1643067     Document Type: Erratum

References (97)

1. NIH CONSENSUS DEVELOPMENT PANEL ON OSTEOPOROSIS PREVENTION, DIAGNOSIS, AND THERAPY: Osteoporosis prevention, diagnosis, and therapy. JAMA (2001) 285:785-795.
2. ROGERS MJ, FRITH JC, LUCKMAN SP: Molecular mechanism of action of bisphosphonate. Bone (1999) 24(5 Suppl.):S73-S79.
3. PACIFICI R: Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J. Bone Miner. Res. (1996) 11:1043-1051.
4. VAANANEN HK, HARKONEN PL: Estrogen and bone metabolism. Maturitas (1996) 23(Suppl.):S65-S69.
5. BOJAR H, DREYFURST R, MAAR K, STAB W: Distribution of oestradiol receptor molecules in human kidney. J. Clin. Chem. Clin. Biochem. (1977) 15:319-321.
6. ARJMANDI BH, SALIH MA, HERBERT DC, SIMS SH, KALU DN: Evidnce for estrogen receprtor-linked calcium transport in the intestine. Bone Miner. (1993) 21:63-74.
7. PRINCE RL, SMITH M, DICK IM et al.: Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N. Engl. J. Med. (1991) 325:1189-1195.
8. REIFENSTEIN ECJ, ALBRAIGHT R: The metabolic effects of steroid hormones in osteoporosis. J. Clin. Invest. (1947) 26:24-56.
9. DRAPER CR, DICK IM, PRINCE RL: The effect of estrogen deficiency on calcium balance in mature rats. Calcif. Tissue Int. (1999) 64:325-328.
10. CRANNEY A, GUYATT G, KROLICKI N et al.; OSTEOPOROSIS RESEARCH ADVISORY GROUP (ORAG): A meta-analysis of eddronate for the treatment of postmenopausal osteoporosis. Osteoporos Int. (2001) 12:140-151.
11. CRANNEY A, GUYATT G, GRIFFITH L, WELLS G, TUGWELL P, ROSEN C, OSTEOPOROSIS METHODOLOGY GROUP AND THE OSTEOPOROSIS RESEARCH ADVISORY GROUP: Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr. Rev. (2002) 23:570-578.
12. WEHREN LE, HOSKING D, HOCHBERG MC: Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. Curr. Med. Res. Opin. (2004) 20:525-531.
13. BUCHER HC, GUYATT GH, COOK DJ, HOLBROOK A, MCALISTER FA: Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA (1999) 282:771-778.
14. BLACK DM, CUMMINGS SR, KARPF DB et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet (1996) 348:1535-1541.
15. CUMMINGS SR, BLACK DM, THOMPSON DE et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA (1998) 280:2077-2082.
16. CRANNEY A, WALDEGGER L, ZYTARUK N et al.: Risedronate for the prevention and treatment of postmenopausal osteoporosis. Cochrane Database Syst. Rev. (2003) 4:CD004523.
17. PAPAPOULOS SE, QUANDT SA, LIBERMAN UA, HOCHBERG MC, THOMPSON DE: Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int. (2005) 16:468-474.
18. MCCLUNG MR, GEUSENS P, MILLER PD et al.: HIP INTERVENTION PROGRAM STUDY GROUP: Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med. (2001) 344:333-340.
19. BOONEN S, LAAN RF, BARTON IP, WATTS NB: Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporas Int. (2005) 16:1291-1298.
20. LIBERMAN UA, HOCHBERG MC, GEUSENS P et al.: Hip and non-spine fracture risk reductions differ among antiresorptive agents: evidence from randomised controlled trials. Int. J. Clin. Pract. (2006) 60:1394-1400.
21. THE WHO SCIENTIFIC GROUP: Prevention and management of osteoporosis. World Health Organ Tech. Rep. Ser. (2003) 921:86-109.
22. JACKSON RD, LACROIX AZ, GASS M et al.: Calcium plus vitamin D supplementation and the risk of fractur-es. N. Engl. J. Med. (2006) 354:669-683.
23. IBERMAN UA, WEISS SR, BROIL J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N. Engl. J. Med. (1995) 333:1437-1443.
24. HARRIS ST, WATTS NB, GENANT HK et al.; VERTEBRAL EFFICACY WITH RISEDRONATE THERAPY (VERT) STUDY GROUP: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA (1999) 282:1344-1352.
25. REGINSTER J, MINNE HW, SORENSEN OH et al.; VERTEBRAL EFFICACY WITH RISEDRONATE THERAPY (VERT) STUDY GROUP: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. (2000) 11:83-91.
26. STORM T, THAMSBORG G, STEINICHE T, GENANT HK, SORENSEN OH: Effect of intermittent cyclical eddronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N. Engl. J. Med. (1990) 322:1265-1271.
27. WATTS NB, HARRIS ST, GENANT HK et al.: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med. (1990) 323:73-79.
28. ETTINGER B, BLACK DM, MITLAK BH et al.: Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA (1999) 282:637-645.
29. MEUNIER PJ, DELMAS PD, EASTELL R et al.: Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin. Ther. (1999) 21:1025-1044.
30. NISHIZAWA Y, NAKAMURA T, OHTA H et al.; COMMITTEE ON THE GUIDELINES FOR THE USE OF BIOCHEMICAL MARKERS OF BONE TURNOVER IN OSTEOPOROSIS JAPAN OSTEOPOROSIS SOCIETY: Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J. Bone Miner. Metab. (2005) 23:97-104.
31. NEER RM, ARNAUD CD, ZANCHETTA JR et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. (2001) 344:1434-1441.
32. MEUNIER PJ, ROUX C, SEEMAN E et al.: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. (2004) 350:459-468.
33. REGINSTER JY, SEEMAN E, DE VERNEJOUL MC et al.: Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. (2005) 90:2816-2822.
34. CHESNUT CH III, SKAG A, CHRISTIANSEN C et al.; ORAL IBANDRONATE OSTEOPOROSIS VERTEBRAL FRACTURE TRIAL IN NORTH AMERICA AND EUROPE (BONE): Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. (2004) 19:1241-1249.
35. DELMAS PD, RECKER PR, CHESNUT CH III et al.: Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk. results from the BONE study. 0steoperos Int. (2004) 15:792-798.
36. HODSMAN AB, BAUER DC, DEMPSTER DW et al.: Parathyroid hormone and teriparatide for the treatment of osteopomsis: a review of the evidence and suggested guidelines for its use. Endocr. Rev. (2005) 26:688-703.
37. HOUGH S, ASCOTT-EVANS B, DE VILLIERS T, DE WEERD J, ELLIS G, LIPSCHITZ S; NATIONAL OSTEOPOROSIS FOUNDATION OF SOUTH AFRICA: Position paper of the National Osteoporosis Foundation of South Africa (NOFSA) on the use of parathyroid hormone (PTH 1-34) in the treatment of osteoporosis. S. Afr. Med. J. (2004) 94:175-177.
38. BONE HG, HOSKING D, DEVOGELAER JP et al.; ALENDRONATE PHASE III OSTEOPOROSIS TREATMENT STUDY GROUP: Ten years'cxperience with alcnctronate for osteoporosis in postmenopausal women. N. Engl. J. Med. (2004) 350:1189-1199.
39. MELLSTROM DD, SORENSEN OH, GOEMAERE S, ROUX C, JOHNSON TD, CHINES AA: Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. (2004) 75:462-468.
40. BLACK DM, SCHWARTZ AV, ENSRUD KE et al.; FLEX RESEARCH GROUP: Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 296:2927-2938.
41. SIRIS ES, HARRIS ST, EASTELL R et aLl. CONTINUING OUTCOMES RELEVANT TO EVISTA (CORE): Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J. Bone Miner Res. (2005) 20:1514-1524.
42. JOHNELL O, SCHEELE WH, LU Y, REGINSTER JY, NEED AG, SEEMAN E: Additive effeccs of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteop orosis. J. Clin. Endocrinol. Metab. (2002) 87:985-992.
43. BLACK DM, GREENSPAN SL, ENSRUD KE et al.; PATH STUDY INVESTIGATORS: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. (2003) 349:1207-1215.
44. BLACK DM, BILEZIKIAN JP, ENSRUD KE et al.; PATH STUDY INVESTIGATORS: One year of alendronate after one year of parathyroid hormone (1-84) fbr osteoporosis. N. Engl. J. Med. (2005) 353:555-565.
45. COSMAN F, NIEVES J, ZION M, WOELFERT L, LUCKEY M, LINDSAY R. Daily and cyclic parathyroid hormone in women receiving alendronate. N. Engl. J. Med. (2005) 353:566-575.
46. SEEMAN E: Unresolved issues in osteoporosis in men. Rev. Endocr. Metab. Disord. (2001) 2:45-64.
47. SEEMAN E: Pathogenesis of bone fragility in women and men. Lancet (2002) 59:1841-1850.
48. KHOSLA S, MELTON LJ III, ATKINSON EJ, O'FALLON WM, KLEE GG, RIGGS BL: Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin. Endocrinol. Metab. (1998) 83:2266-2274.
49. KAMEL HK: Male osteoporosis: new trends in diagnosis and therapy. Drug Aging (2005) 22:741-748.
50. ORWOLL E, ETTINGER M, WEISS S et al.: Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. (2000) 343:604-610.
51. ORWOLL ES, SCHEELE WH, PAUL S et al.: The effect of teriparatide (human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res. (2003) 19:9-17.
52. RINGE JD, ORWOLL E, DAIFOTIS A, LOMBARDI A. Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int. (2002) 13:195-199.
53. RINGE JD, DORST A, FABER H, MACH K: Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm, study. Rheumatol. Int. (2004) 24:110-113.
54. ORWOLL ES, SCHEELE WH, PAUL S et al.: The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res. (2003) 18:9-17.
55. HODGSON SF: Corticosteroid-induced osteoporosis. Endocrinol. Metab. Clin. North Am. (1990) 19:95-111.
56. MANOLAGAS SC: Corticosteroids and fractures: a close encounter of the third cell kind. J. Bone Miner. Res. (2000) 15:1001-1005.
57. VAN STAA TP, LAAN RF, BARTON IP, COHEN S, REID DM, COOPER C: Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. (2003) 48:3224-3249.
58. VAN STAA TP, LEUFKENS HG, COOPER C: The epidemiology of corricosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. (2002) 13:777-787.
59. PEEL NF, MOORE DJ, BARRINGTON NA, BAX DE, EASTELL R: Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann. Rheum. Dis. (1995) 54:801-806.
60. LUENGO M, PICADO C, DEL RIO L, GUANABENS N, MONTSERRAT JM, SETOAIN J: Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax (1991) 46:803-806.
61. DENNISON E: Epidemiology of glucocorticoid-induced. osteoporosis. Osteoporas Int. (1999) 9:S16.
62. KANIS JA, JOHANSSON H, ODEN A et al.: A meta-analysis of prior corticosteroid use and fracture risk. J. Bone Miner. Res. (2004) 19:893-899.
63. VAN STAA TP, LEUFKENS HGM, ABENHAIM L, ZHANG B, COOPER C: Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. (2000) 15:993-1000.
64. MANOLAGAS SC, WEINSTEIN RS: New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J. Bone Miner. Res. (1999) 14:1061-1066.
65. MALOLAGAS SC, WEINSTEIN RS, BELLIDO T, BODENNER DL, JILKA RI, PARFITT AM: Activators of non-genomic estrogen-like signaling (ANGELS): a novel class of small molecules with bone anabolic properties. J. Bone Miner. Res. (1999) 14:S180.
66. WEINSTEIN RS, BELLIDO T, CHAMBERS TM, CRAWFORD JA, SWAIN FL, HAN L: Like estrogen, androgen exerts potent and direct anti-apoptotic cffects on osteoblasts and osteocytes in vivo and in vitro. J. Bone Miner. Res. (1999) 14:S451.
67. PLOTKIN LI, WEINSTEIN RS, PARFITT AM, ROBERSON PK, MANOLAGAS SC, BELLIDO T: Prevention of osteocyte and osteoblasts apoptosis by bisphosphonates and calcitonin. J. Clin. Invest. (1999) 104:1363-1374.
68. JILKA RL, WEINSTEIN RS, BELLIDO T, ROBERSON P, PARFITT AM, MANOLAGAS SC: Increased bone formation by prevention of osteoblast apoptosis with PTH. J. Clin. Invest. (1999) 104:439-446.
69. HOMIK J, SUAREZ-ALMAZOR ME, SHEA B, CRANNEY A, WELLS G, TUGWELL P: Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst. Rev. (2000) 2: CD000952.
70. RICHY F, ETHGEN O, BRUYERE O, REGINSTER JY: Efficacy of α-calcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int. (2004) 15:301-310.
71. CRANNEY A, WELCH V, ADACHI JD et al.: Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Detabase Syst. Rev. (2000) 2:CD001983.
72. HOMIK J, CRANNEY A, SHEA B et al.: Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst. Rev. (2000) 2:CD001347.
73. ADACHI JD, BENSEN WG, BROWN J et al.: Intermittent etidronate therapy to prevent corricosteroid-induced osteoporosis. N. Engl. J. Med. (1997) 337:382-387.
74. SAAG KG, EMKEY R, SCHNITZER TJ et al.; GLUCOCORTICOID-INDUCED OSTEOPOROSIS INTERVENTION STUDY GROUP: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N. Engl. J. Med. (1998) 339:292-299.
75. ADACHI JD, SAAG KG, DELMAS PD et al.: Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. A randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. (2001) 44:202-211.
76. COHEN S, LEVY RM, KELLER M et al.: Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum. (1999) 42:2309-2318.
77. REID DM, HUGHES RA, LAAN R et al.: Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J. Bone Miner. Res. (2000) 15:1006-1013.
78. WALLACH S, COHEN S, REID DM et al.: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. (2000) 67:277-285.
79. LANE NE, SANCHEZ S, MODIN GW, GENANT HK, PIERINI E, ARNAUD C: Bone mass continue to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J. Bone Miner. Res. (2000) 15:944-951.
80. RIZZOLI R, GREENSPAN SL, BONE G III et al.; ALENDRONATE ONCE-WEEKLY STUDY GROUP: Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteopomsis. J. Bone Miner. Res. (2002) 17:1988-1996.
81. SCHNITZER T, BONE HG, CREPALDI G et al.; ALENDRONATE ONCE-WEEKLY STUDY GROUP: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (2000) 12:1-12.
82. SIMON JA, LEWIECKI EM, SMITH ME, PETRUSCHKE RA, WANG I, PALMISANO JJ: Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin. Ther. (2002) 24:1871-1886.
83. ROSEN CJ, HOCHBERG MC, BONNICK SL et al.; THE FOSAMAX ACTONEL COMPARISON TRIAL INVESTIGATORS: Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J. Bone Miner. Res. (2005) 20:141-151.
84. EMKEY R. Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. Med Gen. Med. (2004) 6:6.
85. BROWN JP, KENDLER DL, MCCLUNG MR et al.: The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif. Tissue Int. (2002) 71:103-111.
86. HARRIS ST, WATTS NB, LI Z, CHINES AA, HANLEY DA, BROWN JP: Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr. Med. Res. Opin. (2004) 20:757-764.
87. WATTS NB, LINDSAY R, LI Z, KASIBHATLA C, BROWN J: Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteopoms Int. (2003) 14:437-441.
88. REGINSTER JY, ADAMI S, LAKATOS P et al.: Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann. Rheum. Dis. (2006) 65:654-661.
89. MILLER PD, MCCLUNG MR, MACOVEI L et al.: Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J. Bone Miner. Res. (2005) 20:1315-1322.
90. REGINSTER JY, FELSENBERG D, COOPER C et al.: A new concept for bisphosphonate therapy. a rationale for the development of monthly oral dosing of ibandronate. Osteoporos Int. (2006) 17:159-166.
91. REID IR, BROWN JP, BURCKHARDT P et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. (2002) 346:653-661.
92. DELMAS PD, ADAMI S, STRUGALA C et al.: Intravenous ibandronate injections m postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. (2006) 54:1838-1846.
93. TANVETYANON T, STIFF PJ: Management of the adverse effects associated with intravenous bisphosphonates. Ann. Oncol. (2006) 17:897-907.
94. RUGGIERO SL, MEBROTRA B, ROSENBERG TJ, ENGROFF SL: Osteonecrosis of the jaw associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. (2004) 62:527-534.
95. LENZ JH, STEINER-KRAMMER B, SCHMIDT W, FIETKAU R, MUELLER PC, GUNDLACH KK Does avascular necrosis of the jaw in cancer patients only occur following treatment with bisphosphonates? J. Craniomaxillofac. Surg. (2005) 33:395-403.
96. MARX RE, SAWATARI Y, FORTIN M, BROUMAND V: Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: riskfactors, recognition, prevention, and treatment. J. Maxillofac. Surg. (2005) 63:1567-1575.
97. MCCLUNG MR, LEWIECKI EM, COHEN SB et al.; AMG 162 BONE LOSS STUDY GROUP: Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. (2006) 354:821-831.